Stem cell research provides hope for infertile cancer survivors
Radiation and chemotherapy can pack a powerful punch against all kinds of cancers. Those who survive, however, are often left with bad news: Their treatments have rendered them infertile.
A UTSA professor has now demonstrated that it is possible to remove testicular stem cells from a monkey prior to chemotherapy, freeze them and later, after cancer treatments, transplant these cells where they can restart sperm production and restore fertility.
UTSA Assistant Professor Brian Hermann worked in collaboration with researchers at the University of Pittsburgh School of Medicine's Magee-Womens Research Institute (MWRI) on a technique that might be used to make male cancer patients fertile using their own spermatogonial stem cells.
"This is a really exciting milestone for this research," said John McCarrey, director of the San Antonio Cellular Therapeutics Institute. "This is the first time that anybody has been able to show the concept works in a primate model, and that is an important step in moving the research forward to clinical trials."
While men facing cancer treatments, which could cause infertility, are able to store their own sperm for future use in the fertility clinic, this is not an option for boys before puberty who are not yet making sperm. But, all prepubertal boys have spermatogonial stem cells (SSCs) in their testes, which could be used for transplantation.
The concept of using spermatogonial stem cells to restore fertility was first introduced in the mid-1990s by University of Pennsylvania scholar Ralph L. Brinster. Since that time, scholars have been working to demonstrate the concept is viable.
But more work is required.
The research must overcome a number of hurdles before it can become a common clinical practice.
"This research demonstrates the proof of principle – that the concept works in primates and has a good chance of working in humans," said Hermann. "We need to better understand the optimal timing of transplantation, how to prepare testicular stem cells for transplantation and make them safe for transplantation, and how to maximize their ability to restart sperm production."
But it's hard for researchers to know when clinical trials will begin since the removal and storage of spermatogonial stem cells is currently a rare practice worldwide.
"There are currently only a handful of clinics around the world that will remove and preserve testicular stem cell samples from prepubertal patients, and that limits the availability of candidates," said Hermann. "Until more clinics get on board and save stem cells for patients, we are limited in what we can do to test transplantation in clinical trials."
Hermann joined the UTSA College of Sciences' faculty in summer 2011, following a post-doctoral fellowship at MWRI alongside Associate Professor Kyle Orwig. At UTSA, he is continuing to focus his research on basic and translational studies of spermatogonial stem cells to preserve fertility in boys treated for cancer and related diseases.
"For a long time, oncologists have been unable to address the long-term consequences of life-saving chemotherapy and radiation treatments such as infertility," said Hermann. "That is now beginning to change as laboratory research such as this study provides new experimental options for patients facing infertility after cancer."